Waldenstrom’s Macroglobulinemia

Buske, Christian; Leblond, Véronique

doi:10.1007/978-3-030-55989-2_10

Cited by 3 publications

(3 citation statements)

References 81 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Waldenström's macroglobulinemia (WM) is a rare form of B-cell lymphoproliferative disorder first described in 1944 by Jan Gosta Waldenström. 1 The disease mainly occurs sporadically, but studies indicate that families with a member with WM exhibit a higher risk for the disease. 2 In 20% of WM patients, a deletion in 6(q) is the most common cytogenetic abnormality.…”

Section: Introductionmentioning

confidence: 99%

Waldenström's macroglobulinemia with necrotic extremities: A case with challenging diagnosis

Nekooghadam,

Ghadirzadeh,

Lapevandani

et al. 2023

Clinical Case Reports

View full text Add to dashboard Cite

Key Clinical MessageWaldenström's macroglobulinemia may begin with constitutional symptoms that are common in primary care settings and it is crucial for physicians to be aware of the potential complications of hyperviscosity syndrome and to employ the appropriate diagnostic methods in order to achieve better outcomes.AbstractWaldenström's macroglobulinemia (WM) refers to a type of lymphoplasmacytic lymphoma distinguished by the hyperproliferation of plasma cells, lymphocytes, and plasmacytoid lymphocytes. The disease is primarily diagnosed by increased monoclonal immunoglobulin M (IgM) levels and lymphoplasmacytic cell infiltration into the bone marrow. Individuals exhibit a high risk for hyperviscosity syndrome (HVS) as immunoglobulin levels increase. In addition to constitutional symptoms (fever, night sweats, and unintentional weight loss), clinical findings such as cytopenia, hepatosplenomegaly, and lymphadenopathy, this condition may cause hyperviscosity‐related organ failures. Here we discuss a patient with WM who presented with neurological complaints and blurry vision and developed necrosis at distal portions of his body during the 6‐month course of the disease.

show abstract

Section: Introductionmentioning

confidence: 99%

Waldenström's macroglobulinemia with necrotic extremities: A case with challenging diagnosis

Nekooghadam,

Ghadirzadeh,

Lapevandani

et al. 2023

Clinical Case Reports

View full text Add to dashboard Cite

show abstract

“…Waldenström macroglobulinemia (WM) is a B-cell lymphoplasmacytic lymphoma (LPL) that typically follows an indolent course. 1 It is a relatively uncommon malignancy with roughly 1,500–2,000 new cases diagnosed in the United States. 2 , 3 The median age at presentation is 70 years and prevalence of WM is higher in Caucasian individuals.…”

Section: Introductionmentioning

confidence: 99%

“… 4 Waldenström macroglobulinemia lies on a spectrum of disorders ranging from an immunoglobulin M (IgM) monoclonal gammopathy of undetermined significance (MGUS), to asymptomatic/smoldering WM and eventually symptomatic disease. 1 The common underlying feature in these disorders is the presence of circulating monoclonal IgM protein. Patients with MGUS have a monoclonal IgM protein with less than 10% bone marrow involvement by LPL.…”

Section: Introductionmentioning

confidence: 99%

Treatment paradigm in Waldenström macroglobulinemia: frontline therapy and beyond

Zanwar

Abeykoon

2022

Therapeutic Advances in Hematology

View full text Add to dashboard Cite

Waldenström macroglobulinemia (WM) is an indolent lymphoplasmacytic lymphoma. Recent strides made in the genomic profiling of patients with WM have led to the identification of many novel therapeutic targets. Patients with WM can present with asymptomatic disease and not all patients require treatment. When criteria for initiating systemic therapy are met, the choice of therapy depends on the tumor genotype ( MYD88 and CXCR4 mutation status), patient preference (fixed versus continuous duration therapy, oral versus intravenous route, cost), associated medical comorbidities, and adverse effect profile of the treatment. In the absence of head-to-head comparison between chemoimmunotherapy and Bruton’s tyrosine kinase inhibitors in otherwise fit patients with a MYD88L265P mutation, our preference is fixed duration therapy with four to six cycles of chemoimmunotherapy with bendamustine–rituximab. In this review, we discuss the role of MYD88 and CXCR4 mutation in treatment selection, and current data for frontline and salvage treatment options in patients with WM.

show abstract

Central nervous system involvement (Bing-Neel Syndrome) in patients with Waldenström macroglobulinemia

Zanwar

Abeykoon

Ansell

et al. 2023

Leukemia & Lymphoma

View full text Add to dashboard Cite

Waldenstrom’s Macroglobulinemia

Cited by 3 publications

References 81 publications

Waldenström's macroglobulinemia with necrotic extremities: A case with challenging diagnosis

Waldenström's macroglobulinemia with necrotic extremities: A case with challenging diagnosis

Treatment paradigm in Waldenström macroglobulinemia: frontline therapy and beyond

Central nervous system involvement (Bing-Neel Syndrome) in patients with Waldenström macroglobulinemia

Contact Info

Product

Resources

About